Xin Lu

Xin Lu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
XYXiaobo Yang
Xiaobo Yang
HXHaifeng Xu
Haifeng Xu
BZBangyou Zuo
Bangyou Zuo
XYXu Yang
Xu Yang
JBJin Bian
Jin Bian
HZHaitao Zhao
Haitao Zhao
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy Xiaobo Yang, Haifeng Xu, Bangyou Zuo, Xu Yang, Jin Bian, Junyu Long, Dongxu Wang, Junwei Zhang, Cong Ning, Yanyu Wang, Ziyu Xun, Yunchao Wang, Xin Lu, Yilei Mao, Xinting Sang, Haitao Zhao

10 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JLJianzhen Lin
Jianzhen Lin
LWLiangcai Wu
Liangcai Wu
XBXue Bai
Xue Bai
YXYuan Xie
Yuan Xie
AWAnqiang Wang
Anqiang Wang
HZHaitao Zhao
Haitao Zhao
Combination treatment including targeted therapy for advanced hepatocellular carcinoma

15 January 2019 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
JXJian-Ping Xiong
Jian-Ping Xiong
JLJun-Yu Long
Jun-Yu Long
WXWei-Yu Xu
Wei-Yu Xu
JBJin Bian
Jin Bian
HHHan-Chun Huang
Han-Chun Huang
XLXin Lu
Xin Lu
To clarify the prognostic significance of preoperative albumin-to-alkaline phosphatase ratio (AAPR) in cholangiocarcinoma (CCA) subjects receiving surgery. In this retrospective study, we included 303 CCA patients receiving surgery without preoperative therapy between 2002 and 2014. Clinicopathological characteristics (including AAPR) were analyzed to determine predictors of post-operative overall survival and recurrence-free survival (RFS). In addition, univariate and multivariate Cox proportional hazards models were conducted, followed by application of time-dependent receiver operating curves to identify the optimal cut-off. Univariate and multivariate analyses revealed both decreased overall survival [hazard ratio (HR): 2.88, 95%CI: 1.19-5.78] and recurrence-free survival (HR: 2.31, 95%CI: 1.40-3.29) in patients with AAPR < 0.41 compared to those with AAPR ≥ 0.41. The optimal cut-off of AAPR was 0.41. Of the 303 subjects, 253 (83.5%) had an AAPR over 0.41. The overall 1-, 3- and 5-year survival rates were 70.2%, 38.0% and 16.5%, respectively in the low (< 0.41) AAPR group, which were significantly lower than those in the high (≥ 0.41) AAPR group (81.7%, 53.9%, and 33.4%, respectively) (P < 0.0001). Large tumor size, multiple tumors, and advanced clinical stage were also identified as significant predictors of poor prognosis. Our outcomes showed that AAPR was a potential valuable prognostic indicator in CCA patients undergoing surgery, which should be further confirmed by prospective studies. Moreover, it is necessary to investigate the mechanisms concerning the correlation of low AAPR with poor post-operative survival in CCA patients.

3 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JXJianping Xiong
Jianping Xiong
HZHaoaohai Zhang
Haoaohai Zhang
YWYaqin Wang
Yaqin Wang
AWAnqiang Wang
Anqiang Wang
JBJin Bian
Jin Bian
HZHaitao Zhao
Haitao Zhao
Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis

1 April 2017 in Medicine
Verified
Journal Article
Open access
PDF file
JBJin Bian
Jin Bian
AWAnqiang Wang
Anqiang Wang
JLJianzhen Lin
Jianzhen Lin
LWLiangcai Wu
Liangcai Wu
HHHanchun Huang
Hanchun Huang
HZHaitao Zhao
Haitao Zhao
Several studies have shown that proton pump inhibitors (PPIs) use can increase the risk of developing hepatic encephalopathy (HE) in patients with liver dysfunction. However, no definite conclusion is drawn because of study design limitations. Therefore, we conducted a meta-analysis to explore the association between PPIs and HE. We searched PubMed, EMBASE, and the Cochrane Library from inception until November 2016. Data from the identified studies were combined using a random effects model, and odds ratios (ORs) were calculated. Three case-control studies were included. Compared with nonusers, hepatic insufficiency patients receiving PPIs therapy had a significantly increased risk of developing HE (OR = 1.76, 95% CI: 1.15–2.69), with notable heterogeneity (I2 = 61.4%, P = .075) and publication bias. No relevance was found between PPIs and HE after using the trim and fill method (OR = 1.360, 95%CI: 0.909–2.035, P = .135). PPIs are associated with a higher risk of HE among patients with chronic and acute liver dysfunction. A final conclusion cannot be drawn because of the limited number of studies and a lack of prospective studies.

3 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZZZijun Zhao
Zijun Zhao
JBJin Bian
Jin Bian
JZJunwei Zhang
Junwei Zhang
TZTing Zhang
Ting Zhang
XLXin Lu
Xin Lu
Introduction: Hyperprogressive disease (HPD) is a paradoxically rapid disease progression during or shortly after antitumor treatment, especially immune checkpoint inhibitors (ICIs). Various diagnosis criteria of HPD cause heterogeneous incidence rates in different clinical research, and there is no consensus on potential risk factors associated with HPD occurrence. Hence, we aimed to summarize incidence of HPD in ICI treatment for solid tumors. Clinicopathological factors associated with HPD are also analyzed.Methods: Clinical studies about HPD during/after ICI treatment of solid malignancies are included. Pubmed, Embase, and Cochrane library were searched for eligible studies published before October 7. The Newcastle–Ottawa scale was used to assess the quality of the included studies. Random effect and fixed effect models were, respectively, used for pooling incidence of HPD and analysis of risk factors for HPD. Heterogeneity, subgroup analysis, and publication bias were also analyzed. All meta-analysis was performed via R software (y -40v4.0.2).Results: Forty-one studies with 6009 patients were included. The pooled incidence of HPD was 13.2% (95% CI, 11.2%–15.4%). Head and neck cancer (HNC) had the highest incidence of HPD (18.06%), and melanoma had the lowest (9.9%). Tumor types (P = .0248) and gender ratio (P = .0116) are sources of heterogeneity of pooled incidence of HPD. For five clinicopathological factors associated with HPD, only programmed cell death protein 1 ligand 1 (PD-L1) positivity was a preventive factor (odds ratio = 0.61, P <.05). High lactate dehydrogenase (LDH) level (OR = 1.51, P = .01), metastatic sites >2 (OR = 2.38, P <.0001), Eastern Cooperative Oncology Group Performance Score ≥2 (OR = 1.47, P = .02), and liver metastasis (OR = 3.06, P <.0001) indicate higher risk of HPD.Conclusions: The pooled incidence of HPD was less than 15%, and HNC had the highest incidence of HPD. LDH and PD-L1 are remarkable biomarkers for prediction of HPD in future medical practice.